Hepatitis B

President Donald Trump signed an executive order recommending revamped childhood vaccine guidelines, including separating the MMR vaccine and altering universal Hepatitis B recommendations. Public health expert Dr. Georges Benjamin heavily criticized the changes, warning they would create additional burdens for parents and move away from established medical practices. Senator Bill Cassidy also stated that the new executive order was wrong.

Pediatricians and health departments are avoiding the CDC's vaccine guidance due to changes under the Trump administration, including the replacement of the CDC's vaccine advisory board with anti-vaccine appointees. The CDC removed several vaccines from the recommended schedule, prompting legal challenges and confusion among healthcare providers and the public.

The Africa Centres for Disease Control and Prevention (Africa CDC) released the Operational Toolkit for the Prevention, Diagnosis and Management of Hepatitis B. The document is described as a deliberately practical resource for addressing the health challenge.

Kano state is intensifying efforts to eliminate mother-to-child transmission of HIV, Hepatitis B, and Syphilis. Mr. Yusuf highlighted that these infections are largely preventable, with syphilis being curable when detected and treated early.

The WHO urges Africa to expand access to hepatitis care as viral hepatitis remains a major public health challenge despite a 25% decline in new hepatitis B infections between 2015 and 2024.

The American Medical Association criticized President Trump's executive order to align US childhood vaccine recommendations with Denmark's, which would reduce recommended immunizations from 17 to 11. The AMA stated the current vaccine schedule is based on decades of research and US-specific disease data.

An experimental hepatitis B drug called bepirovirsen may offer a 'functional cure' for some patients, with 20% of trial participants maintaining undetectable virus levels after stopping treatment. Developed by GSK and Ionis Pharmaceuticals, the drug is under fast-track FDA review and shows potential to address chronic hepatitis B, which affects over 250 million people globally.

Scientists report early progress in engineered heart patches and GSK announces a functional cure for hepatitis B. The article also highlights potential drug launches tied to President Trump's 'most-favored nation' claims and previews the upcoming ASCO meeting in Chicago.

The article promotes STAT’s free daily health newsletter 'Morning Rounds,' highlighting topics like Ebola, hepatitis B, and long Covid. It includes a call to sign up and mentions the author’s personal reading distractions.

An experimental hepatitis B treatment, GSK’s bepirovirsen, achieved functional cures in 20% and 19% of patients in Phase 3 trials, significantly outperforming current treatments that achieve 1-3% success rates. The drug showed no functional cures in placebo groups, offering hope for a more effective solution to a disease affecting 250-300 million people globally.

Genome editing is highlighted as a risky technology, but a new approach called epigenome editing is introduced as a potential solution. The technology aims to address diseases such as atherosclerosis and hepatitis B.

Bill Cassidy, a Louisiana Republican senator and doctor, faces a dilemma as he questions Health Secretary Robert F. Kennedy Jr. in Senate hearings, balancing his loyalty to President Trump with his advocacy for vaccines. Kennedy's controversial anti-vaccine policies and recent shifts in public health messaging could impact Cassidy's reelection bid and congressional oversight of health programs.